Evidence map›Paper›PMID 39153976›Full record

ArticleBMC pulmonary medicine2024

Treatment patterns in patients with newly diagnosed COPD in the USA.

Antonio Anzueto, Sheri Rogers, Bonnie Donato, Beverly Jones, Kushal Modi, Abisola Olopoenia, Robert Wise

Abstract read
In one paragraph

Article in BMC pulmonary medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Proactive Strategies for Mitigating Cardiopulmonary Risk in COPD.Federal practitioner : for the health care professionals of the VA, DoD, and PHS · 2025
    Article
  5. Article
  6. Burden of Exacerbations in Patients Newly Initiating an Inhaled Regimen for COPD: A Claims Analysis.International journal of chronic obstructive pulmonary disease · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Antonio AnzuetoSouth Texas Veterans Healthcare System, Division of Pulmonary Diseases/Critical Care Medicine, University of Texas Health, 111 E 7400 Merton Minter Blvd, San Antonio, TX, 78229, USA. anzueto@uthscsa.edu.
Sheri RogersBoehringer Ingelheim Inc, Ridgefield, CT, USA.
Bonnie DonatoBoehringer Ingelheim Inc, Ridgefield, CT, USA.
Beverly JonesBoehringer Ingelheim Inc, Ridgefield, CT, USA.
Kushal ModiCerner Enviza, New York, NY, USA.
Abisola OlopoeniaCerner Enviza, New York, NY, USA.
Robert WisePulmonary and Critical Care Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPrompt and effective management with maintenance therapy (single or dual bronchodilator therapy) is recommended after the initial diagnosis of chronic obstructive pulmonary disease (COPD) to maintain lung function and prevent exacerbations. Contrary to guideline-based recommendations, most patients are not prescribed maintenance treatment at initial diagnosis. The current study assessed the pharmacologic treatment patterns and outcomes of newly diagnosed patients with COPD in the USA.

methodsThis retrospective, noninterventional study used de-identified data from the Inovalon Insights' database (Commercial, Medicaid Managed Care, and Medicare Advantage-insured individuals) between January 1, 2015, and December 31, 2021. The "patient journey" from initial diagnosis was followed over a 4-year period. The primary outcome measure was the number of moderate or severe exacerbations. Secondary outcome measures included the cumulative incidence of exacerbations, mean cumulative count of moderate and severe exacerbations, rates of moderate and severe exacerbations in patients who remained untreated after diagnosis in 12-month time periods for 4 years, sociodemographic and clinical characteristics, and pharmacologic treatment patterns.

resultsThe cohort consisted of 238,158 newly diagnosed patients with COPD (female [52.9%]; mean age 63.8 years). The majority of patients with COPD had Medicaid as their primary insurance (46.2%). Overall, during the 4-year follow-up period, 32.9% of the patients had at least one moderate or severe exacerbation, and 25.8% and 13.8% experienced moderate and severe exacerbations, respectively. At diagnosis, 86.2% of the patients were untreated and most remained untreated by the end of the follow-up (63.8%). Most patients (62.0%) received long-acting beta-agonist (LABA)/inhaled corticosteroids (ICS) as their initial treatment at diagnosis, and LABA/ICS continued to be the most common initial treatment during the 4-year period (64.0% at year 1; 58.0% at year 4).

conclusionsMost patients with COPD were not treated at initial diagnosis and remained untreated during follow-up. Our data highlight a lack of adherence to recommendations for clinical practice.

Indexed as

Bronchodilator AgentsPulmonary Disease, Chronic ObstructiveAgedDatabases, FactualDisease ProgressionFemaleHumansMaleMedicaidMiddle AgedPractice Patterns, Physicians'Retrospective StudiesUnited StatesBronchodilator AgentsCOPDExacerbationsMaintenance therapyNewly diagnosedTreatment patterns

Identifiers

PMID39153976
PMCPMC11330015

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.